iShares U.S. Pharmaceuticals ETF (IHE) is a healthcare and biotech ETF. As of October 28, 2026, ETF Copilot scores IHE 6.0 out of 10 — highest on Quality (8.9), lowest on Value (1.8). It trades at 29.7 times earnings, against its own median of 22.9. Its ten largest holdings are 80% of the fund.
What stands out in IHE's data
U.S. pharmaceutical manufacturers, held through a market-cap-weighted index.
Priced roughly in line with the health-care sector — no bargain, but no premium for the name.
Trailing P/E multiple of 29.7x sits near the category median of 29.6x. Its EBITDA margin of 37.3% runs well above the peer norm of 21.9%.
A sector-specific position in drug makers, for portfolios that want targeted health-care exposure.
Why did IHE move this week? It rose 0.9% in the week to October 28, 2026 — Johnson & Johnson and Eli Lilly drove it
IHE rose 0.9% in the week to October 28, 2026. The holdings that moved it most were Johnson & Johnson (+5.1%), Eli Lilly (+1.4%) and Royalty Pharma (+4.3%); Corcept Therapeutics (−25.8%) pushed the other way.
How is IHE rated? ETF Copilot scores iShares U.S. Pharmaceuticals ETF (IHE) 6.0 out of 10
As of October 28, 2026, ETF Copilot scores iShares U.S. Pharmaceuticals ETF (IHE) 6.0 out of 10 overall.
ETF Copilot scores (0–10 scale, higher is better):
- Overall: 6.0 / 10
- Growth: 5.1 / 10
- Value: 1.8 / 10
- Risk: 7.6 / 10
- Quality: 8.9 / 10
- Return: 6.7 / 10
Is IHE expensive right now? It trades at 29.7 times earnings, against its own median of 22.9
As of October 28, 2026, IHE is more expensive than 99% of its own last 9 years.
Trailing 12 months, built from IHE's holdings. How we calculate this →
What's inside IHE?
What's inside IHE: Size (Large 66%, Mid 21%, Small 13%); Geography (International 3%, US 97%).
What are IHE's top holdings? The ten largest are 80% of the fund
Eli Lilly, Johnson & Johnson, Zoetis, Pfizer, Royalty Pharma, Viatris, Bristol-Myers Squibb, Merck, Jazz Pharmaceuticals and Elanco Animal Health are IHE's largest holdings, in that order.
More concentrated than 99% of Health & Biotech ETFs.
Half of IHE's weight sits in its 3 largest positions, and once those weights are taken into account it behaves like 8 equally weighted holdings.
What is IHE's expense ratio? 0.37% a year
As of October 28, 2026, IHE charges 0.37% a year, yields 1.37% and holds $1.6B in assets across 56 positions.
| Measure | IHE |
|---|---|
| Expense ratio | 0.37% |
| Dividend yield | 1.37% |
| Assets under management | $1.6B |
| Holdings | 56 |
Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.
Cite this
ETF Copilot, “iShares U.S. Pharmaceuticals ETF (IHE) scores and holdings analysis”, as of October 28, 2026.
https://etf-copilot.com/etf/ihe
ETF Copilot Pro unlocks IHE's price and what each holding weighs.
Try Pro free →